TE-031 (A-56268) in treatment of respiratory tract infections

Seiichi Aonuma, Yutaka Tokue, Naoto Kitamura, Yoshihiro Honda, Reiko Ono, Akira Watanabe, Masako Sasaki, Kotaro Oizumi, Kiyoshi Konno, Kosaku Nagai

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)


    TE-031 (A-56268), a new macrolide antibiotic, was administered to patients with respiratory tract infections, and its clinical and bacteriological efficacy and safety were investigated. The 17 patients (13 males and 4 females, ranging in age from 23∼82 years) consisted of one case of acute pharyngitis, 10 of acute bronchitis, 4 of chronic respiratory tract infection (one each of chronic emphysema, bronchiectasis, inveterate pleurisy and inveterate pulmonary tuberculosis), and 2 of pneumonia. TE-031 was orally administered in a dose of 150 mg twice a day for 5∼14 days. The evaluation of clinical efficacy was 10 good, 3 fair, and 4 poor cases, with an efficacy rate of 58.8%. Studies on bacteriological efficacy revealed that one strain of P. vulgaris was eradicated, while one of S. pneumoiae was replaced by H. influenzae and one of E. faecalis by K. pneumoniae, and one each of K. pneumoniae and P. aeruginosa remained unchanged. None of the patients developed sideeffects or abnormal laboratory test values.

    Original languageEnglish
    Pages (from-to)549-552
    Number of pages4
    Publication statusPublished - 1988 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology


    Dive into the research topics of 'TE-031 (A-56268) in treatment of respiratory tract infections'. Together they form a unique fingerprint.

    Cite this